Serum thymidine kinase 1 is associated with Gleason score of patients with prostate carcinoma

Li,Shujing; Zhou,Jianping; Wang,Yu; Zhang,Keqin; Yang,Junjie; Zhang,Xinling; Wang,Chunmei; Ma,Hongbo; Zhou,Ji; He,Ellen; Skog,Sven

doi:10.3892/ol.2018.9345

Serum thymidine kinase 1 is associated with Gleason score of patients with prostate carcinoma

Authors:
- Shujing Li
- Jianping Zhou
- Yu Wang
- Keqin Zhang
- Junjie Yang
- Xinling Zhang
- Chunmei Wang
- Hongbo Ma
- Ji Zhou
- Ellen He
- Sven Skog
View Affiliations

Affiliations: Department of Nephrology, Southwest Hospital, Third Military Medical University, Chongqing 400030, P.R. China, Radioimmunity Center, Shaanxi Provincial People's Hospital, Xian, Shaanxi 710068, P.R. China, Health Management Center, People's Liberation Army 180 Hospital, Quanzhou, Fujian 362000, P.R. China, Department of Urology, Daping Hospital, Third Military Medical University, Chongqing 400042, P.R. China, Department of Medicine, Sino‑Swed Molecular Bio‑Medicine Research Institute, Shenzhen, Guangdong 518057, P.R. China
Published online on: August 21, 2018 https://doi.org/10.3892/ol.2018.9345
Pages: 6171-6180

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present was to assess whether serum thymidine kinase 1 (STK1) concentration is a useful biomarker for the screening of benign prostatic hyperplasia (BPH) or prostate malignancy. Serum samples were collected from 123 patients with prostate carcinoma prior to surgery, biopsy or androgen deprivation therapy and at 3, 6 and 10 months following the procedure. A total of 205 patients with BPH and 266 healthy controls were also utilized. STK1 concentration and total prostate‑specific antigen (PSA) were measured in patient serum by use of commercial assays. The pathological specimens (obtained from surgery or biopsy) were assessed according to Gleason scores (GS). STK1 concentration and total PSA were significantly higher in patients with prostate carcinoma compared with patients with BPH and healthy individuals. Furthermore, STK1 concentration was associated with Gleason score, while total PSA was not. However, no association was identified between STK1 concentration and total serum PSA. A receiver operating characteristic analysis was performed on STK1 concentrations among patients with prostate carcinoma. The results demonstrated that the sensitivity and specificity were high, with an area under the curve (AUC) of 0.97. Although the sensitivity and specificity of total PSA were also high, the AUC value was relatively low (0.74). The results indicated that STK1 concentration is a more reliable prognostic biomarker than total PSA in respect to the GS system. Additionally, since STK1 concentration is associated with Gleason score, the use of biopsies to determine Gleason score may be replaced to some extent by the STK1 concentration test, thus reducing the discomfort of patients from which biopsies are obtained.

View Figures

View References

1	Global Burden of Disease Cancer Collaboration, ; Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, et al: The global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015. View Article : Google Scholar : PubMed/NCBI
2	Hoffman RM, Meisner AL, Arap W, Barry M, Shah SK, Zeliadt SB and Wiggins CL: Trends in United States prostate cancer incidence rates by age and stage, 1995–2012. Cancer Epidemiol Biomarkers Prev. 25:259–263. 2016. View Article : Google Scholar : PubMed/NCBI
3	Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttönen L, Lilja H, et al: Screening and prostate cancer mortality: Results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet. 384:2027–2035. 2014. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
5	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
6	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
7	Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep. 50:125–128. 1966.PubMed/NCBI
8	Amin MB, Schultz DS and Zarbo RJ: Analysis of cribriform morphology in prostatic neoplasia using antibody to high-molecular-weight cytokeratins. Arch Pathol Lab Med. 118:260–264. 1994.PubMed/NCBI
9	Epstein JI, Allsbrook WC Jr, Amin MB and Egevad LL: The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–1242. 2005. View Article : Google Scholar : PubMed/NCBI
10	Eggener SE, Badani K, Barocas DA, Barrisford GW, Cheng JS, Chin AI, Corcoran A, Epstein JI, George AK, Gupta GN, et al: Gleason 6 prostate cancer: Translating biology into population health. J Urol. 194:626–634. 2015. View Article : Google Scholar : PubMed/NCBI
11	Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR and Humphrey PA; Grading Committee, : The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 40:244–252. 2016.PubMed/NCBI
12	Gordetsky J and Epstein J: Grading of prostatic adenocarcinoma: Current state and prognostic implications. Diagn Pathol. 11:252016. View Article : Google Scholar : PubMed/NCBI
13	Suzuki H, Komiya A, Kamiya N, Imamoto T, Kawamura K, Miura J, Suzuki N, Nakatsu H, Hata A and Ichikawa T: Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. Urology. 67:131–136. 2006. View Article : Google Scholar : PubMed/NCBI
14	Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, et al: Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer. 111:1201–1212. 2014. View Article : Google Scholar : PubMed/NCBI
15	Epstein JI, Feng Z, Trock BJ and Pierorazio PM: Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: Incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 61:1019–1024. 2012. View Article : Google Scholar : PubMed/NCBI
16	Pezaro CJ, Omlin A, Lorente D, Nava RD, Ferraldeschi R, Bianchini D, Mukherji D, Riisnaes R, Altavilla A, Crespo M, et al: Visceral disease in castration-resistant prostate cancer. Eur Urol. 65:270–273. 2014. View Article : Google Scholar : PubMed/NCBI
17	Ramakrishnan VM, Bossert K, Singer G, Lehmann K and Hefermehl LJ: The impact of the 2005 International Society of Urological Pathology Gleason grading consensus on active surveillance for prostate cancer. Cent European J Urol. 70:344–348. 2017.PubMed/NCBI
18	Lima NG, Soares Dde F and Rhoden EL: Importance of prostate-specific antigen (PSA) as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens. Clinics (Sao Paulo). 68:820–824. 2013. View Article : Google Scholar : PubMed/NCBI
19	Liu X, Chen X, Rycaj K, Chao HP, Deng Q, Jeter C, Liu C, Honorio S, Li H, Davis T, et al: Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells. Oncotarget. 6:23959–23986. 2015.PubMed/NCBI
20	Sfanos KS and De Marzo AM: Prostate cancer and inflammation: The evidence. Histopathology. 60:199–215. 2012. View Article : Google Scholar : PubMed/NCBI
21	Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, et al: Comparative analysis of prostatespecific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 109 Suppl 1:S22–S29. 2012. View Article : Google Scholar
22	Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, et al: Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 177:2106–2131. 2007. View Article : Google Scholar : PubMed/NCBI
23	Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC and Kane RL: Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Int Med. 148:435–448. 2008. View Article : Google Scholar : PubMed/NCBI
24	Mitchell JM: Urologists' use of intensity-modulated radiation therapy for prostate cancer. N Engl J Med. 369:1629–1637. 2013. View Article : Google Scholar : PubMed/NCBI
25	Ilic D, Neuberger MM, Djulbegovic M and Dahm P: Screening for prostate cancer. Cochrane Database Syst Rev. 31:CD0047202013.
26	Herschman JD, Smith DS and Catalona WJ: Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology. 50:239–243. 1997. View Article : Google Scholar : PubMed/NCBI
27	Pron G: Prostate-specific antigen (PSA)-based population screening for prostate cancer: An evidence-based analysis. Ont Health Technol Assess Ser. 15:1–64. 2015.
28	Skog S, He E and Haghdoost S: Prevention and early detection of human tumor. LAP Lambert Academic Publishing; pp. 742017
29	Wu JT: Circulating tumor markers of the new millennium. AACC Press; New York, NY: pp. 115–117. 2002
30	Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH, Schmidlin F, Miralbell R and Zanetti R: Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer. 123:421–429. 2008. View Article : Google Scholar : PubMed/NCBI
31	Zhou J, He E and Skog S: The proliferation marker thymidine kinase 1 in clinical use (Review). Mol Clin Oncol. 1:18–28. 2013. View Article : Google Scholar : PubMed/NCBI
32	Letocha H, Eklöv S, Gronowitz S, Norlen BJ and Nilsson S: Deoxythymidine in staging of prostatic carcinoma. Prostate. 29:15–19. 1996. View Article : Google Scholar : PubMed/NCBI
33	Li SJ, Wu G, Ye J, Zhang X, Cheng F, Zhang KQ and Yan-Feng J: The purpose of blood serum thymidine kinase level in early screening of prostatic carcinoma. Immun J. 27:459–461. 2011.
34	Jagarlamudi KK, Hansson LO and Eriksson S: Breast and prostate cancer patients differ significantly in their serum thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: Implications of using serum TK1 as a biomarker. BMC Cancer. 15:662015. View Article : Google Scholar : PubMed/NCBI
35	Aufderklamm S, Hennenlotter J, Todenhoefer T, Gakis G, Schilling D, Vogel U, Kuehs U, Dlugosch J, Knapp J, Merseburger A, et al: XPA-210: A new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence. World J Urol. 30:547–552. 2012. View Article : Google Scholar : PubMed/NCBI
36	Na Y, Sun Z, Ye Z and Sun Y: Guidelines for the diagnosis and treatment of Urology Surgery in ChinaIII Guidelines for the diagnosis and treatment of prostate cancer. Ming L, Su G and He D: People's Health Press; Beijing: pp. 32–84. 2007
37	Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, et al: Prostate cancer screening in men aged 50–69 years (STHLM3): A prospective population-based diagnostic study. Lancet Oncol. 16:1667–1676. 2015. View Article : Google Scholar : PubMed/NCBI
38	Chen ZH, Huang SQ, Wang Y, Yang AZ, Wen J, Xu XH, Chen Y, Chen QB, Wang YH, He E, et al: Serological thymidine kinase 1 is a biomarker for early detection of tumours-a health screening study on 35,365 people using a sensitive chemiluminescent dot blot assay. Sensor (Basel). 11:11064–11080. 2011. View Article : Google Scholar